MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

NCT00797667 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

660

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated based on a recommendation of the DSMB following the identification of two patients with significant elevations in serum transaminases

Conditions

Migraine

Interventions

DRUG: Telcagepant 140 mg
DRUG: Telcagepant 280 mg
DRUG: 140 mg telcagepant placebo
DRUG: 280 mg telcagepant placebo

Sponsor

Merck Sharp & Dohme LLC